Synergistic Effects of Silver Nanoparticles and Beta-Lactam Antibiotics Against Multi-Drug Resistant Staphylococcus aureus
- Apr 18
- 1 min read
Updated: May 14
Original Research | 2026 | Volume-3 | Issue-1 | Page 23-29
Dinesh Kumar, MSc. Microbiology, Sai Institute of Paramedical and Allied Sciences, Dehradun, Uttrakhand, 248001
Dr Abdul Majid Khan, Assistant Professor. Prince Medical College and Hospital Sikar Rajasthan
Dr. Akansha Puri, Senior Resident, Prince Medical College and Hospital Sikar Rajasthan
Dinesh Kumar, MSc. Microbiology,
Sai Institute of Paramedical and
Allied Sciences, Dehradun, Uttrakhand, 248001
Abstract
Background: The rise of multi-drug resistant (MDR) Staphylococcus aureus poses a critical threat to global public health, rendering conventional beta-lactam antibiotics increasingly ineffective. Silver nanoparticles (AgNPs) have emerged as potent antimicrobial agents due to their unique physicochemical properties and multiple mechanisms of action.
Objective: This study investigates the synergistic potential of combining AgNPs with traditional beta-lactam antibiotics to restore bacterial susceptibility and enhance therapeutic efficacy against MDR S. aureus.
Methods: Silver nanoparticles were synthesized and characterized using UV-Vis spectroscopy and TEM. The antibacterial activity of AgNPs and beta-lactams (Penicillin, Amoxicillin) was evaluated individually and in combination using disc diffusion and Checkerboard titration methods to determine the Fractional Inhibitory Concentration (FIC) index.
Results: Results demonstrated that AgNPs significantly lowered the Minimum Inhibitory Concentration (MIC) of beta-lactam antibiotics. The combination exhibited a marked synergistic effect, characterized by enlarged zones of inhibition and FIC indices < 0.5. This synergy is attributed to AgNPs disrupting bacterial cell wall integrity, thereby facilitating antibiotic penetration and inhibiting beta-lactamase activity.
Conclusion: The integration of AgNPs with beta-lactams represents a promising "re-sensitization" strategy to combat MDR S. aureus, potentially extending the clinical lifespan of existing antibiotics and providing a robust alternative to current failing treatments.